This article has been updated from a previous version.
NEW YORK, July 17 – Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Japanese pharmaceutical company Kyowa-Hakko Kogyo, the companies announced Tuesday.
The license, which includes access to human, mice, and rat data, is for two years and is an all-cash agreement with payments up-front each year, said Eli Mintz, president of Compugen. The company would not disclose the license fee.
“This is a great validation for the Gencarta technology in the Japanese market,” said Mintz, who added that Compugen sees Japan as a growing market for its products.
“We chose Compugen’s Gencarta database and mining tools because of its exceptional transcriptome analysis,” Seiga Itoh, senior executive officer, drug discovery division of Tokyo-based Kyowa-Hakko, said in a statement. “We expect that the integration of Compugen's proprietary and comprehensive gene and protein database into our research will significantly advance our drug discovery and development processes.”
Compugen released Gencarta in March. The database uses Compugen’s Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins.
The agreement with Kyowa-Hakko is Compugen’s second customer for Gencarta. In April, Avalon Pharmaceuticals of Gaithersburg, MD, licensed the database.